Tim Meyer

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng et al. · New England Journal of Medicine · 2018 · 2.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu et al. · Journal of Clinical Oncology · 2020 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Arndt Vogel, Andrés Cervantes, Ian Chau et al. · Annals of Oncology · 2018 · 1.1K citations · Full text

Medicine, Oncology, Surgery +14